Literature DB >> 2418291

Electrophysiological effects of encainide and its metabolites in 11 patients.

C C Libersa, J P Lekieffre, J F Caron, J M Poirier, A M Pladys, S Kacet, A R Kher.   

Abstract

Encainide is a new antiarrhythmic class IC agent. Eleven patients were given 1 mg/kg of encainide i.v. over a 15-min period. Electrophysiological studies were done before and l h after drug administration. Blood levels of encainide and its principle metabolites O-demethyl-encainide, 3 metoxy-O-demetyl-encainide and N-demethyl-encainide were measured serially after drug administration. Heart rate, blood pressure, and conduction intervals were monitored. Sixty minutes after drug administration there was a marked increase of the QRS, PA, AH, and HV intervals of 28.1% (p less than 0.01), 17.2% (p less than 0.01), 22.4% (p less than 0.01), and 32.2% (p less than 0.01), respectively, and a slight increase of the Wenckebach cycle length of 8% (p less than 0.05). BP, RR, QT, CSNRT, ESACT, ERP, and FRP did not vary significantly. The HV interval already was increased significantly 2 min after drug administration, while AH was not increased until 15 min after drug administration. The average blood levels of encainide and ODE 60 min after drug administration were 0.410 +/- 0.12 and 0.176 +/- 0.09 microgram/ml, respectively (mean +/- SE of the mean). There was a positive correlation between the increase of the AH and the blood level of ODE, which points out the importance of prolonged electrophysiological studies when testing drug with possibly active metabolites.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2418291     DOI: 10.1097/00005344-198511000-00010

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

Review 1.  Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.

Authors:  S Nattel
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 2.  In-vitro and in-vivo electrophysiologic effects of encainide.

Authors:  C Libersa; J Caron; R Rouet
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

Review 3.  Encainide. A review of its pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.